



European Cystic Fibrosis Society Diagnostic Network Working Group

Coordinator: Elke De Wachter

http://www.ecfs.eu/ecfs_dnwg



19th Annual Meeting, Virtual meeting
Wed 9th - Fri 11th February 2022 (3x ½ day)

Organizing committee:

Caroline Raynal, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
Elke De Wachter, ECFS DNWG Coordinator, UZ Brussel, VUB, Brussels, Belgium
Nick Simmonds, ECFS DNWG co-coordinator, Brompton Hospital, London, UK
Marlies Destoop, ECFS DNWG Assistant, UZ Brussel, VUB, Brussels, Belgium

Scientific Program



Wednesday 9th February 2022 (9:00-12:00)

"CFTR-RD-day": Day1

09.00 Welcome – Caroline Raynal (Montpellier, France) & Elke De Wachter (Brussels, Belgium)

Session 1: CFTR-RD Day Part 1

(Kevin Southern - Elke De Wachter)

9:10 CFTR-RD: the need to revisit the diagnosis and follow-up
Carlo Castellani (Genova, Italy)

9:30 The final CFTR-RD diagnosis should ultimately be decided by the level of CFTR-dysfunction
Isabelle Sermet (Paris, France)

9:50 The final CFTR-RD diagnosis should ultimately be decided by clinical features
Kris De Boeck (Leuven, Belgium)

10:10 Discussion

10:20 Break - 15 min

Session 2: CFTR-RD Day Part 2

(Chairs: Kris De Boeck- Nick Simmonds)

10:35 The CFTR-RD clinic: different from the CF clinic?
Nick Simmonds (London, UK)

10:55 ABPA: in and outside the CF clinic
Lieven Dupont (Leuven, Belgium)

11:15 Bronchiectasis in and outside the CF clinic
Peter Middleton (Sydney, Australia)

11:35 Discussion

11:45 Wrap up Day 1
Nick Simmonds (London, UK)



Thursday 10th February 2022 (9:00-12:30)

"CFTR-RD-day": Day2

9:00 Welcome to Day2

Session 3: CFTR-RD Day Part 3

(Chairs: Caroline Raynal - Marlies Destoop)

9:10 CBAVD through the eyes of a geneticist
Emmanuelle Girodon (Paris, France)

9:30 CBAVD through the eyes of a fertility doctor
Veerle Vloeberghs (Brussels, Belgium)

9:50 Primary sclerosing cholangitis and recurrent pancreatitis through the eyes of a gastroenterologist
Michael Wilschanski (Jerusalem, Israel)

10:10 Aquagenic wrinkling through the eyes of a dermatologist
Smail Hadj Rabia (Paris, France)

10:30 Discussion

10:40 Break - 15 min

Session 4: CFTR-RD Day Part 4

(Chairs: Elke De Wachter - Inez Bronsveld)

10:55 CFTR-modulators for all CFTR-RD: PRO
Eitan Kerem (Jerusalem, Israel)

11:15 CFTR-modulators for all CFTR-RD: CON
François Vermeulen (Leuven, Belgium)

11:35 Discussion

11:45 YI-1: Complex CFTR alleles in the context of altered in vitro response to CFTR modulators
Eva Furstova (Prague, Czech Republic) *(10 min talk - 5 min discussion)*

12:00 YI-2: Airway and lung organoids from human induced pluripotent stem cells may potentially be used for predicting cystic fibrosis patient-specific drug response
Anna Demchenko (Moscow, Russia) *(10 min talk - 5 min discussion)*

12:15 Wrap up Day 2
Elke De Wachter (Brussels, Belgium)



Friday 11th February 2022 (9:00-12:30)

9:00 Welcome to Day 3

Session 5: CFSPID

(Chairs: Dorota Sands- Karin Winter de Groot)

9:10 When to move from CFSPID to CF?
Jürg Barben (St Gallen, Switzerland)

9:30 From CFSPID to CFTR-RD: what is known?
Kevin Southern (Liverpool, UK)

9:50 CFSPID to «nothing»: when to let go?
Anne Munck (Paris, France)

10:10 Discussion

10.20 Break -15min

Session 6: Biomarkers

(Chairs: Isabelle Sermet- Burkhart Tümmler)

10:35 ECFS-latest ST paper
Natalia Cirilli (Ancona, Italy)

10:55 The beta-adrenergic sweat test landscape - who does which technique and where
Paola Mellotti (Verona, Italy)

11:15 NPD validation study
Inez Bronsveld (Utrecht, The Netherlands)

11:35 Discussion

11:45 YI-3: The β -adrenergic sweat secretion test using the AutoBuSTeD software as a novel, high-sensitive diagnostic tool for patients with inconclusive CFTR genotype and sweat chloride concentration
Sophia Pallenberg (Hannover, Germany) (10 min talk - 5 min discussion)

12:00 YI-4: Validation of a new interpretation of the intestinal current measurement in a group of patients in a diagnostic setting
Anne-Marie Mosch (Utrecht, The Netherlands) (10 min talk - 5 min discussion)

12:15 Closing remarks: Elke De Wachter and Nick Simmonds



This meeting is kindly supported by